Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial. // American Heart Journal. – URL: https://www.sciencedirect.com/science/article/pii/S0002870326003133?dgcid=rss_sd_all
Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial. American Heart Journal. https://www.sciencedirect.com/science/article/pii/S0002870326003133?dgcid=rss_sd_all
“Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial.” American Heart Journal.
@article{article34738,
title = {Apixaban Benefit in Subclinical Atrial Fibrillation Accounting for Competing Risks: A Reanalysis of the ARTESIA Trial},
journal = {American Heart Journal},
url = {https://www.sciencedirect.com/science/article/pii/S0002870326003133?dgcid=rss_sd_all}
}